ArticleBMC neurology2026
Epidemiology of unspecified degenerative nervous system disorders: mortality trends via CDC WONDER (1999-2025).
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnspecified degenerative nervous system disorders (ICD-10 G31.9) increasingly contribute to neurological mortality, yet national temporal patterns remain unclear.
methodsWe analyzed U.S. mortality data (1999–2025) from CDC WONDER. Age-adjusted mortality rates (AAMRs) were analyzed using Joinpoint regression to estimate annual percent changes (APCs), stratified by sex, race, urbanization, and census regions. Sensitivity analyses assessed stability.
resultsOverall, AAMR increased from 0.66 per 1,000,000 in 1999 to 1.44 per 1,000,000 in 2025. The trend showed four joinpoints: from 1999 to 2011 (APC 1.34%, p < 0.05), a sharp rise from 2011 to 2014 (15.79%, p < 0.05), a decline from 2014 to 2018 (-3.14%, p < 0.05), a rise from 2018 to 2021 (13.38%, p < 0.05), and a decrease thereafter (-1.89%, p < 0.05). Females showed early increases, whereas males were stable before 2011. Racial and regional analyses revealed heterogeneity, with post-2010 increases in several groups. Metropolitan areas showed persistent increases, while nonmetropolitan trends fluctuated. Sensitivity analyses confirmed findings.
conclusionMortality from G31.9 disorders shows changing trends, varying across demographics and regions. These differences highlight gaps in diagnosis and care, emphasizing the need for targeted public health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.